Mediaomics, Life Sciences Finalist, participated in the poster & networking session during the 2nd ed. Grand Finale Ceremony.

1. Problem: Our unique solution:
Low Biomedicines Productivity Our technology selects the right
ingredients for maximum productivity
High production costs (Patent pending in Portugal)
Systemic manufacturing capacity shortage
Team members Benefits:
- 2x productivity
Rui Oliveira, Ph.D. - For existing capacity:
100% increase production capacity
- Biomedicines market - 9.9 % AAGR - For new capacity:
- New plant costs 1 B USD 50% reduction of fixed Capex
António Dinis, MBA
Our proposition: Market:
João Dias, Ph.D.
Pichia-FEM: Overall culture media market :
- 760 M USD in 2009
High performance chemically - 8.6 % AAGR
Nuno Carinhas, Ph.D. defined medium - Estimated 2.21 B USD in 2022
Pricing (Clinical Trial:
Filipe Ataíde, Ph.D. student - R&D: 57 €/L
- PC and Phase I: 27 €/L
Customers:
- Phases II and III: 15 €/L
- Commercial: 6 €/L
Ana Ferreira, Ph.D. student
- 2x productivity compared to industry's
gold standard (BSM from Invitrogen)
- Consistently maintains productivity
increase for 0.1, 2 and 50 L
Pichia-SER:
Customized media development
- Services will be provided on a project-basis
- Supplements to add to Pichia-FEM
- Locks-in future Pichia-FEM sales Roadmap:
Competitors:
Partnerships already established with:
- P. pastoris clone development company
- Process development company
- Culture media distributor (preliminary talks)
Financials:
- Investment: 2 million EUR
- NPV: 1.3 million EUR
- Sales (2017): 5 million EUR
- Value (2017): 21-25 million EUR
- EBIDTA multiples: 10-12x